Tripotassium bismuth dicitrate 120 mg 56 pcs. film-coated tablets
pharmachologic effect
A drug that has a protective effect on the mucous membrane of the stomach and duodenum. Antiulcer drug.
Composition and release form Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets
Tablets - 1 tablet:
- Active substances: bismuth tripotassium dicitrate - 304.6 mg, which corresponds to the content of bismuth oxide - 120 mg;
- Excipients: corn starch - 71.1 mg, potassium polyacrylate - 23.6 mg, povidone K25 - 17.7 mg, macrogol 6000 - 6 mg, magnesium stearate - 2 mg;
- Film shell composition: hypromellose - 5.5 mg; titanium dioxide - 3 mg; macrogol-4000 - 1.5 mg.
7, 8, 10, 14, 28, 30, 50, 56, 60, 100, 112, 160 or 240 pcs. — cardboard cell packaging or polyethylene terephthalate cans (1, 2, 3, 4, 5, 6, 7, 8, 10, 16) — cardboard packs.
Description of the dosage form
Tablets, film-coated, white or almost white, round, biconvex, odorless or with a weak characteristic odor; two layers are visible on the cross section: a core of white or white with a yellowish tint and a film shell.
Directions for use and doses
Adults and children over 4 years old - orally 2-4 times a day 30 minutes before meals. The dose depends on the patient's age.
The course of treatment is 4-8 weeks. You should not take medications containing bismuth for the next 8 weeks.
To eradicate Helicobacter pylori, it is advisable to use bismuth tripotassium dicitrate in combination with antibacterial drugs that have anti-Helicobacter activity.
Pharmacodynamics
Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are formed, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.
Pharmacokinetics
Bismuth tripotassium dicitrate is practically not absorbed from the gastrointestinal tract. However, small amounts of bismuth may enter the systemic circulation. It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted by the kidneys.
Indications for use Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets
Peptic ulcer of the stomach and duodenum in the acute phase (including those associated with Helicobacter pylori); chronic gastritis and gastroduodenitis in the acute phase (including those associated with Helicobacter pylori); irritable bowel syndrome, which occurs predominantly with symptoms of diarrhea; functional dyspepsia not associated with organic gastrointestinal diseases.
Contraindications
Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate.
Application of Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets during pregnancy and breastfeeding
Contraindicated for use during pregnancy and lactation (breastfeeding).
It is used in children over 4 years of age according to the dosage regimen.
special instructions
Should not be used for more than 8 weeks.
During treatment, it is not recommended to exceed the established daily doses for adults and children.
At the end of the course of treatment in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 μg/l, and intoxication is observed only at a concentration of more than 100 μg/l.
During use, stool may turn black due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.
Side effects of Bismuth tripotassium dicitrate 120 mg 56 pcs. film-coated tablets
From the digestive system: transient effects are possible - nausea, vomiting, increased bowel movements, constipation.
Dermatological reactions: skin rash, itching.
From the side of the central nervous system: with long-term use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system.
Drug interactions
If you take other medicines at the same time, as well as food and liquids, in particular antacids, milk, fruit and fruit juices, the effectiveness of bismuth tripotassium dicitrate may change.
Tripotassium bismuth dicitrate tablet film 120 mg x56
BISMUTH TRIPOTASSIUM DICITRATE Bismuth tripotassium citrate
,
,
Compound
1 tablet contains the active substance: bismuth tripotassium citrate - 304.6 mg, in terms of bismuth oxide - 120.0 mg.
Pharmacotherapeutic group
Antiulcer, antiseptic, intestinal and astringent
ATX code
А02ВХ05
pharmachologic effect
Gastroprotective and antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. Thus, the drug forms a protective layer, which for a long period of time protects the affected areas of the mucous membrane from the influence of aggressive factors. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsipogen.
Indications for use
• functional dyspepsia not associated with organic diseases of the gastrointestinal tract, • chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori, • peptic ulcer of the stomach and duodenum in the acute phase, including those associated with Helicobacter pylori, • syndrome irritable bowel disease, occurring predominantly with symptoms of diarrhea.
Contraindications
• increased individual sensitivity to the components of the drug, • pregnancy, • breastfeeding, • taking medications containing bismuth, • chronic renal failure, • children under 4 years of age.
Method of administration and dosage
Inside. The duration of the course of treatment and the dose of the drug are determined by the attending physician individually for each patient, depending on the nature of the disease. For adults and children over 12 years of age, the drug is prescribed 1 tablet 4 times a day, 30 minutes before meals (breakfast, lunch, dinner) and at night, or 2 tablets 2 times a day 30 minutes before meals (breakfast, dinner). Children aged 8 to 12 years are prescribed 1 tablet 2 times a day, 30 minutes before meals (breakfast, dinner). Children aged 4 to 8 years are prescribed at a dose of 8 mg/kg/day, depending on the child’s body weight, 1-2 tablets per day are prescribed (respectively, in 1-2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). The tablets are taken 30 minutes before meals with a small amount of water. It is recommended to swallow the tablet whole, without chewing or crushing, with a sufficient amount of water. It is not recommended to take the tablets with milk. The duration of treatment is usually from 4 to 8 weeks. After finishing taking the drug, it is not recommended to take medications containing bismuth (for example, Vikalin, Vikair) for 2 months. For eradication of Helicobacter pylori, it is advisable to use bismuth tripotassium citrate in combination with antibacterial drugs with anti-Helicobacter activity.
Release form
Film-coated tablets 120 mg. 7, 10, 14, 28, 30 tablets in blister packs made of polyvinyl chloride film and printed varnished aluminum foil. 7, 10, 14, 20, 28, 30, 50, 56, 60, 100, 112, 160 or 240 tablets in polyethylene terephthalate jars for medicines or polypropylene for medicines, sealed with high-density polyethylene lids with first opening control or polypropylene lids with a “push-turn” system or low-density polyethylene lids with first-opening control.
Terms of release from pharmacies
Available without a prescription.
Proton pump inhibitors (PPIs)
PPI therapy has proven effective in various clinical studies. Although PPIs have a direct antibacterial effect on H. pylori in vitro, they do not play an important role in eradicating the infection.
The mechanism by which PPIs synergize when combined with antimicrobials to enhance the clinical efficacy of eradication therapy has not been fully established. It is assumed that antisecretory drugs of the PPI group may help increase the concentration of antimicrobial agents, in particular metronidazole and clarithromycin, in the gastric lumen. PPIs reduce the volume of gastric juice, as a result of which the leaching of antibiotics from the surface of the mucosa decreases, and the concentration, accordingly, increases. In addition, reducing the volume of hydrochloric acid maintains the stability of antimicrobials.
Bismuth tripotassium dicitrate
BISMUTH TRIPOTASSIUM DICITRATE Bismuth tripotassium citrate
,
,
Compound
1 tablet contains the active substance: bismuth tripotassium citrate - 304.6 mg, in terms of bismuth oxide - 120.0 mg.
Pharmacotherapeutic group
Antiulcer, antiseptic, intestinal and astringent
ATX code
А02ВХ05
pharmachologic effect
Gastroprotective and antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. Thus, the drug forms a protective layer, which for a long period of time protects the affected areas of the mucous membrane from the influence of aggressive factors. By increasing the synthesis of prostaglandin E, mucus formation and bicarbonate secretion, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsipogen.
Indications for use
• functional dyspepsia not associated with organic diseases of the gastrointestinal tract, • chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori, • peptic ulcer of the stomach and duodenum in the acute phase, including those associated with Helicobacter pylori, • syndrome irritable bowel disease, occurring predominantly with symptoms of diarrhea.
Contraindications
• increased individual sensitivity to the components of the drug, • pregnancy, • breastfeeding, • taking medications containing bismuth, • chronic renal failure, • children under 4 years of age.
Method of administration and dosage
Inside. The duration of the course of treatment and the dose of the drug are determined by the attending physician individually for each patient, depending on the nature of the disease. For adults and children over 12 years of age, the drug is prescribed 1 tablet 4 times a day, 30 minutes before meals (breakfast, lunch, dinner) and at night, or 2 tablets 2 times a day 30 minutes before meals (breakfast, dinner). Children aged 8 to 12 years are prescribed 1 tablet 2 times a day, 30 minutes before meals (breakfast, dinner). Children aged 4 to 8 years are prescribed at a dose of 8 mg/kg/day, depending on the child’s body weight, 1-2 tablets per day are prescribed (respectively, in 1-2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day). The tablets are taken 30 minutes before meals with a small amount of water. It is recommended to swallow the tablet whole, without chewing or crushing, with a sufficient amount of water. It is not recommended to take the tablets with milk. The duration of treatment is usually from 4 to 8 weeks. After finishing taking the drug, it is not recommended to take medications containing bismuth (for example, Vikalin, Vikair) for 2 months. For eradication of Helicobacter pylori, it is advisable to use bismuth tripotassium citrate in combination with antibacterial drugs with anti-Helicobacter activity.
Release form
Film-coated tablets 120 mg. 7, 10, 14, 28, 30 tablets in blister packs made of polyvinyl chloride film and printed varnished aluminum foil. 7, 10, 14, 20, 28, 30, 50, 56, 60, 100, 112, 160 or 240 tablets in polyethylene terephthalate jars for medicines or polypropylene for medicines, sealed with high-density polyethylene lids with first opening control or polypropylene lids with a “push-turn” system or low-density polyethylene lids with first-opening control.
Terms of release from pharmacies
Available without a prescription.
Indications for eradication therapy
According to the Maastricht 2-2000 Consensus Report, H. pylori eradication is strongly recommended:
- all patients with peptic ulcer disease;
- patients with poorly differentiated MALT lymphoma;
- persons with atrophic gastritis;
- after resection for gastric cancer;
- first-degree relatives of patients with stomach cancer.
The need for eradication therapy in patients with functional dyspepsia, GERD, as well as in persons taking non-steroidal anti-inflammatory drugs for a long time remains a subject of debate. There is no evidence that eradication of H. pylori in such patients affects the course of the disease. However, it is well known that individuals with H. pylori who have nonulcer dyspepsia and corpus-predominant gastritis are at increased risk of developing gastric adenocarcinoma. Thus, H. pylori eradication should also be recommended for patients with nonulcer dyspepsia, especially if histology reveals corpus-predominant gastritis.
The argument against anti-Helicobacter therapy in patients taking NSAIDs is that the body protects the gastric mucosa from the damaging effects of drugs by increasing cyclooxygenase activity and prostaglandin synthesis, while PPIs reduce natural defenses. However, eradication of H. pylori before prescribing NSAIDs significantly reduces the risk of peptic ulcer disease during subsequent treatment (a study by American scientists led by Francis K. Chan, published in The Lancet in 1997).
Aksamon solution d/im/sc injected 5 mg/ml 1 ml x10
ATX code: N07AA (Anticholinesterase drugs) Active substance: ipidacrine (ipidacrine) Rec.INN registered by WHO Dosage form AKSAMON solution for intramuscular and subcutaneous administration 5 mg/ml: 1 ml amp. 10 pieces. reg. No.: LP-002247 dated 09.25.13 - Valid Release form, composition and packaging Solution for intramuscular and subcutaneous administration in the form of a clear, colorless liquid.
1 ml ipidacrine hydrochloride (as monohydrate) 5 mg
Excipients: hydrochloric acid - up to pH 3.0, water for injection - up to 1 ml.
1 ml - glass ampoules (5) - contour cell packaging made of polyvinyl chloride film (2) - cardboard packs.
Clinical and pharmacological group: Cholinesterase inhibitor Pharmaco-therapeutic group: Anticholinesterase drug Pharmacological action Information on the drug is available only to specialists. Login or Register Indications Diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, polyradiculopathy), bulbar palsy and paresis.
In the recovery period for organic lesions of the central nervous system, accompanied by motor disorders.
Myasthenia, myasthenic syndrome.
Demyelinating diseases (as part of complex therapy).
Alzheimer's disease, senile dementia of the Alzheimer's type.
Functional disorders of the central nervous system (decreased memory, ability to concentrate, motivation, initiative, disorientation, emotional lability, etc.) with encephalopathy (traumatic, vascular and other origins), cerebrovascular accident, traumatic brain injury, cerebral dysfunction with learning disabilities children.
Weakness of labor.
Intestinal atony.
Intoxication with anticholinergic drugs.
ICD-10 codes ICD-10 code Indication F00 Dementia in Alzheimer's disease F07 Personality and behavioral disorders caused by disease, damage or dysfunction of the brain G30 Alzheimer's disease G60 Hereditary and idiopathic neuropathy G61 Inflammatory polyneuropathy G62.1 Alcoholic polyneuropathy G63.2 Diabetic polyneuropathy G70 .2 Congenital or acquired myasthenia M54.1 Radiculopathy M79.2 Neuralgia and neuritis, unspecified O62 Disturbances of labor [birth forces]
Dosage regimen: Orally, subcutaneously, intramuscularly. Single dose – 10-40 mg. The maximum dose is 200 mg/day. The frequency of administration and duration of treatment depend on the indications. Side effects From the digestive system: anorexia, hypersalivation, nausea, vomiting, increased peristalsis, diarrhea, jaundice.
From the side of the central nervous system: dizziness (after repeated use), ataxia.
Allergic reactions: skin rash, itching.
Other: manifestations of m-cholinergic stimulating effect - bronchospasm, bradycardia.
Contraindications for use Epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, bronchial asthma, tendency to vestibular disorders, pregnancy, lactation, hypersensitivity to ipidacrine. Use during pregnancy and lactation Contraindicated during pregnancy and lactation. Special instructions: Use with caution in case of gastric ulcer, thyrotoxicosis, diseases of the cardiovascular system. It is necessary to take into account the ability of ipidacrine to increase uterine tone.
Impact on the ability to drive vehicles and operate machinery
It should not be used in patients whose activities involve driving vehicles and work that requires high concentration and speed of psychomotor reactions.
Clarithromycin
Clarithromycin, a 14-member macrolide, is a derivative of erythromycin with a similar spectrum of activity and indications for use. However, unlike erythromycin, it is more acid resistant and has a longer half-life. The results of studies showing that the triple eradication therapy regimen for Helicobacter pylori using clarithromycin gives a positive result in 90% of cases, led to the widespread use of the antibiotic.
In this regard, an increase in the prevalence of clarithromycin-resistant strains of H. pylori has been recorded in recent years. There is no evidence that increasing the dose of clarithromycin will overcome the problem of antibiotic resistance to the drug.
